Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-AF: Asundexian vs Apixaban for Stroke Prevention in Atrial Fibrillation
NCT05643573Phase 3Terminated
- Sponsor
- Bayer
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of asundexian in Atrial fibrillation (AFib) (2 arms), sponsored by Bayer. Primary endpoints: Composite of Stroke or Systemic Embolism at 12 months, International Society on Thrombosis and Hemostasis Major Bleeding at 12 months and 1 more. Started Dec 2022; status: terminated.
02
Drugs
asundexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05643573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643573.